{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:19:45Z","timestamp":1793837985278,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Res Involv Engagem"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients themselves are best placed to provide insights on the lived experience and to lead the analysis of such insights to bring the patient voice into peer-reviewed literature. In doing so, they can meet the authorship criteria for subsequent research publications. It is important to evaluate patient engagement to identify ways to improve future collaborations. Here, we describe the approach taken during a patient-led and patient co-authored analysis of the lived experience of generalized myasthenia gravis, which may be applicable to other indications. We also assessed the quality of patient engagement throughout the research project.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used self-reported experience surveys based on the Patient Focused Medicines Development Patient Engagement Quality Guidance criteria for assessing patient engagement. The surveys were adapted to focus on individual projects and assessed eight domains using a five-point Likert scale. In September 2020, we invited eight patient council members to complete a self-reported experience survey following qualitative lived experience data generation. We calculated the average experience score as a percentage of the maximum possible score. Patient authors (n\u2009=\u20091) and non-patient authors (n\u2009=\u20093) were invited to complete a similar survey in November 2021, with questions customized for relevance, to evaluate the authorship experience following publication of the research.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, patient council members had a positive experience of taking part in this study, with an average experience score of 90% (71.6\/80.0; n\u2009=\u20098). The patient author and non-patient authors rated their authorship experience highly, with average experience scores of 92% (78.0\/85.0) and 97% (63.3\/65.0), respectively. There were key aspects that contributed to the overall project success (e.g., ensuring that all participants were aligned on the project objectives at the outset and understood their roles and responsibilities). We also identified elements of the approach that could be improved in future collaborations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this patient-led analysis, patient council members, patient authors and non-patient authors had a positive experience of being involved in the project. We gained useful insights into elements that contributed to the project\u2019s success and ways to improve future patient-led projects on the lived experience.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40900-023-00445-2","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T14:03:12Z","timestamp":1685023392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of the quality of patient involvement in a patient-led analysis of the lived experience of a rare disease"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-4857","authenticated-orcid":false,"given":"Dawn","family":"Lobban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqui","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Davio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenza","family":"Seddik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3067-8678","authenticated-orcid":false,"given":"Veronica","family":"Porkess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"445_CR1","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1177\/2168479015580384","volume":"49","author":"A Hoos","year":"2015","unstructured":"Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Ther Innov Regul Sci. 2015;49:929\u201339.","journal-title":"Ther Innov Regul Sci"},{"key":"445_CR2","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/2168479017706405","volume":"51","author":"J Geissler","year":"2017","unstructured":"Geissler J, Ryll B, di Priolo SL, Uhlenhopp M. Improving patient involvement in medicines research and development: a practical roadmap. Ther Innov Regul Sci. 2017;51:612\u20139.","journal-title":"Ther Innov Regul Sci"},{"key":"445_CR3","unstructured":"United States Food & Drug Administration. Patient listening sessions. https:\/\/www.fda.gov\/patients\/learn-about-fda-patient-engagement\/patient-listening-sessions. Accessed 22 March 2023."},{"key":"445_CR4","unstructured":"European Medicines Agency. Patients and consumers. https:\/\/www.ema.europa.eu\/en\/partners-networks\/patients-consumers. Accessed 22 March 2023."},{"key":"445_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/medethics-2012-101215","volume":"40","author":"G Olthuis","year":"2014","unstructured":"Olthuis G, Leget C, Grypdonck M. Why shared decision making is not good enough: lessons from patients. J Med Ethics. 2014;40:493\u20135.","journal-title":"J Med Ethics"},{"key":"445_CR6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/1049732315570116","volume":"25","author":"L Garrino","year":"2015","unstructured":"Garrino L, Picco E, Finiguerra I, Rossi D, Simone P, Roccatello D. Living with and treating rare diseases: experiences of patients and professional health care providers. Qual Health Res. 2015;25:636\u201351.","journal-title":"Qual Health Res"},{"key":"445_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.21307\/ajon-2017-112","volume":"25","author":"T Keer-Keer","year":"2015","unstructured":"Keer-Keer T. The lived experience of adults with myasthenia gravis: a phenomenological study. Australas J Neurosci. 2015;25:40\u20136.","journal-title":"Australas J Neurosci"},{"key":"445_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13012-018-0784-z","volume":"13","author":"Y Bombard","year":"2018","unstructured":"Bombard Y, Baker GR, Orlando E, Fancott C, Bhatia P, Casalino S, et al. Engaging patients to improve quality of care: a systematic review. Implement Sci. 2018;13:98.","journal-title":"Implement Sci"},{"key":"445_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40900-021-00290-1","volume":"7","author":"KD Cobey","year":"2021","unstructured":"Cobey KD, Monfaredi Z, Poole E, Proulx L, Fergusson D, Moher D. Editors-in-chief perceptions of patients as (co) authors on publications and the acceptability of ICMJE authorship criteria: a cross-sectional survey. Res Involv Engagem. 2021;7:39.","journal-title":"Res Involv Engagem"},{"key":"445_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40900-020-00190-w","volume":"6","author":"L Arnstein","year":"2020","unstructured":"Arnstein L, Wadsworth AC, Yamamoto BA, Stephens R, Sehmi K, Jones R, et al. Patient involvement in preparing health research peer-reviewed publications or results summaries: a systematic review and evidence-based recommendations. Res Involv Engagem. 2020;6:34.","journal-title":"Res Involv Engagem"},{"key":"445_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40900-022-00346-w","volume":"8","author":"J Oliver","year":"2022","unstructured":"Oliver J, Lobban D, Dormer L, Walker J, Stephens R, Woolley K. Hidden in plain sight? Identifying patient-authored publications. Res Involv Engagem. 2022;8:12.","journal-title":"Res Involv Engagem"},{"key":"445_CR12","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","volume":"10","author":"N Law","year":"2021","unstructured":"Law N, Davio K, Blunck M, Lobban D, Seddik K. The lived experience of myasthenia gravis: a patient-led analysis. Neurol Therapy. 2021;10:1103\u201325.","journal-title":"Neurol Therapy"},{"key":"445_CR13","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023\u201336.","journal-title":"Lancet Neurol"},{"key":"445_CR14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3109\/08916931003602130","volume":"43","author":"JJ Verschuuren","year":"2010","unstructured":"Verschuuren JJ, Palace J, Gilhus NE. Clinical aspects of myasthenia explained. Autoimmunity. 2010;43:344\u201352.","journal-title":"Autoimmunity"},{"key":"445_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.nmd.2020.06.010","volume":"30","author":"AM Ruiter","year":"2020","unstructured":"Ruiter AM, Verschuuren J, Tannemaat MR. Fatigue in patients with myasthenia gravis: a systematic review of the literature. Neuromuscul Disord. 2020;30:631\u20139.","journal-title":"Neuromuscul Disord"},{"key":"445_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5:30.","journal-title":"Nat Rev Dis Primers"},{"key":"445_CR17","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3889\/oamjms.2018.110","volume":"6","author":"N Tanovska","year":"2018","unstructured":"Tanovska N, Novotni G, Sazdova-Burneska S, Kuzmanovski I, Boshkovski B, Kondov G, et al. Myasthenia gravis and associated diseases. Open Access Maced J Med Sci. 2018;6:472\u20138.","journal-title":"Open Access Maced J Med Sci"},{"key":"445_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-9562.1000317","volume":"6","author":"B Cacho Diaz","year":"2015","unstructured":"Cacho Diaz B, Flores-Gavilan P, Garcia-Ramos G, Lorenzana-Mendoza NA. Myasthenia Gravis and its comorbidities. J Neurol Neurophysiol. 2015;6:1\u20135.","journal-title":"J Neurol Neurophysiol"},{"key":"445_CR19","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/104973299129122289","volume":"9","author":"B Paterson","year":"1999","unstructured":"Paterson B, Thorne S, Crawford J, Tarko M. Living with diabetes as a transformational experience. Qual Health Res. 1999;9:786\u2013802.","journal-title":"Qual Health Res"},{"key":"445_CR20","unstructured":"Envision the Patient. Patient authorship resources. https:\/\/www.patientauthorship.com\/. Accessed 22 March 2023."},{"key":"445_CR21","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1212\/WNL.0000000000011772","volume":"96","author":"K Davio","year":"2021","unstructured":"Davio K, Law N, Blunck M, Seddik K. The lived experience of Myasthenia Gravis (MG): a patient-led analysis. Neurology. 2021;96:2272.","journal-title":"Neurology"},{"key":"445_CR22","doi-asserted-by":"publisher","unstructured":"Adis journals on behalf of; Law N, Davio K, Blunck M, Lobban D, Seddik K. Patient author video. The lived experience of myasthenia gravis: a patient-led analysis. 2022. https:\/\/doi.org\/10.6084\/m9.figshare.19175462.v2.","DOI":"10.6084\/m9.figshare.19175462.v2"},{"key":"445_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3453","volume":"358","author":"S Staniszewska","year":"2017","unstructured":"Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. BMJ. 2017;358: j3453.","journal-title":"BMJ"},{"key":"445_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40900-017-0062-2","volume":"3","author":"S Staniszewska","year":"2017","unstructured":"Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. Res Involv Engagem. 2017;3:13.","journal-title":"Res Involv Engagem"},{"key":"445_CR25","unstructured":"Patient Focused Medicine Development. Patient engagement quality guidance. 2018. https:\/\/patientfocusedmedicine.org\/peqg\/patient-engagement-quality-guidance.pdf. Accessed 22 March 2023."},{"key":"445_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/03007995.2019.1587943","volume":"35","author":"KL Woolley","year":"2019","unstructured":"Woolley KL, Arnstein L, Hamoirm AM, Lobban D, Stephens R, Yamamoto B. Original abstracts from the 15th Annual Meeting of ISMPP. Development and use of two tools to facilitate and evaluate patient authorship. Curr Med Res Opin. 2019;35:5\u201329.","journal-title":"Curr Med Res Opin"},{"key":"445_CR27","unstructured":"Patient Focused Medicine Development. The PFMD Book of Good Practices: Patient involvement in preparing clinical research peer-reviewed publications or results summaries: a systematic review. 2019. https:\/\/patientfocusedmedicine.org\/bogp\/2019\/the-book-of-good-practices.pdf. Accessed 22 March 2023."},{"key":"445_CR28","doi-asserted-by":"publisher","unstructured":"Richards DP, Poirier S, Mohabir V, Proulx L, Robins S, Smith J. Reflections on Patient Engagement by Patient Partners: How it can go Wrong. 2023. Preprint at https:\/\/doi.org\/10.31219\/osf.io\/q3e76.","DOI":"10.31219\/osf.io\/q3e76"},{"key":"445_CR29","unstructured":"National Health Council. Patient-focused drug development \u2013 recommended language for use in guidance document development. 2017. http:\/\/www.nationalhealthcouncil.org\/sites\/default\/files\/NHC-GA%20Feb2017.pdf. Accessed 22 March 2023."},{"key":"445_CR30","doi-asserted-by":"publisher","first-page":"e27141","DOI":"10.2196\/27141","volume":"13","author":"U Ellis","year":"2021","unstructured":"Ellis U, Kitchin V, Vis-Dunbar M. Identification and reporting of patient and public partner authorship on knowledge syntheses: rapid review. J Particip Med. 2021;13:e27141.","journal-title":"J Particip Med"},{"key":"445_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40900-020-00213-6","volume":"6","author":"DP Richards","year":"2020","unstructured":"Richards DP, Birnie KA, Eubanks K, Lane T, Linkiewich D, Singer L, et al. Guidance on authorship with and acknowledgement of patient partners in patient-oriented research. Res Involv Engagem. 2020;6:38.","journal-title":"Res Involv Engagem"},{"key":"445_CR32","unstructured":"Woolley K, Yamamoto BA, Stephens R, Lobban D, Ebina H, Arnstein L. Patient authorship: three key questions (& answers!) for medical communication professionals [part A]. The MAP Newsletter. 2020. https:\/\/ismpp-newsletter.com\/2020\/05\/13\/patient-authorship-three-key-questions-answers-for-medical-communication-professionals-part-a\/. Accessed 22 March 2023."},{"key":"445_CR33","unstructured":"Woolley K, Yamamoto BA, Stephens R, Lobban D, Ebina H, Arnstein L. Patient authorship: three key questions (& answers!) for medical communication professionals [part B]. The MAP Newsletter. 2020. https:\/\/ismpp-newsletter.com\/2020\/05\/26\/patient-authorship-three-key-questions-answers-for-medical-communication-professionals-part-b\/. Accessed 22 March 2023."},{"key":"445_CR34","doi-asserted-by":"publisher","first-page":"eL220490","DOI":"10.7326\/L22-0490","volume":"176","author":"LM DeTora","year":"2023","unstructured":"DeTora LM, Lane T, Sykes A, DiBiasi F, Toroser D, Citrome L. Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2023;176:eL220490.","journal-title":"Ann Intern Med"},{"key":"445_CR35","unstructured":"WECAN, Envision Pharma Group. Patients in Publications training course. 2021. https:\/\/wecanadvocate.eu\/patients-in-publications\/. Accessed 22 March 2023."},{"key":"445_CR36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/03007995.2022.2055262","volume":"38","author":"J Oliver","year":"2022","unstructured":"Oliver J, Porkess V, McSorley S, Lobban D. Measuring the quality of patient engagement in a patient-led and co-authored analysis of the lived experience of a rare disease. Original abstracts from the 18th annual meeting of ISMPP. Curr Med Res Opin. 2022;38:5\u201324.","journal-title":"Curr Med Res Opin"}],"container-title":["Research Involvement and Engagement"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40900-023-00445-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40900-023-00445-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40900-023-00445-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T14:03:19Z","timestamp":1685023399000},"score":1,"resource":{"primary":{"URL":"https:\/\/researchinvolvement.biomedcentral.com\/articles\/10.1186\/s40900-023-00445-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["445"],"URL":"https:\/\/doi.org\/10.1186\/s40900-023-00445-2","relation":{},"ISSN":["2056-7529"],"issn-type":[{"value":"2056-7529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"30 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Neither the global qualitative study nor the patient council\u2013led analysis was an investigation of clinical outcomes with any intervention. The global qualitative study adhered to local market research guidelines in the countries included and was conducted in accordance with EphMRA Code of Conduct. Therefore, neither ethics committee approval nor clinical trial registration was required. The patients who participated in the qualitative research study were fully informed of the purpose of research, provided consent to participate and agreed for their data to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Members of the patient council consented to the publication of their insights and analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DL and JO are employees and shareholders of Envision Pharma Group. KD is a member of the patient council. KS and VP are employees of UCB Pharma. DL, KD and KS were participants in the authorship experience survey described in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}